<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571372</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0620</org_study_id>
    <nct_id>NCT04571372</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease</brief_title>
  <official_title>Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the association between level of suPAR and valvular heart disease in&#xD;
      patients who have severe aortic stenosis or severe aortic regurgitation using commercially&#xD;
      available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse clinical outcomes</measure>
    <time_frame>Immediate post operation</time_frame>
    <description>Composite of all-cause death, cardiovascular mortality, and worsening of kidney function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse clinical outcomes</measure>
    <time_frame>2 years after recruiting</time_frame>
    <description>Composite of all-cause death, cardiovascular mortality, and worsening of kidney function</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Severe Aortic Stenosis or Severe Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>Patients with severe aortic stenosis or severe aortic regurgitation</arm_group_label>
    <description>Patients with severe aortic stenosis or severe aortic regurgitation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis or severe aortic regurgitation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 19 yrs&#xD;
&#xD;
          -  Severe aortic stenosis or severe aortic regurgitation&#xD;
&#xD;
          -  Agree to consent for self&#xD;
&#xD;
          -  Can follow-up for the next 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing acute kidney injury&#xD;
&#xD;
          -  Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15&#xD;
             ml/min/1.73m2 or receiving renal replacement therapy&#xD;
&#xD;
          -  On ECMO or IABP&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiwon Seo</last_name>
    <phone>82-2-2228-8464</phone>
    <email>jiwonseo1430@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiwon Seo</last_name>
      <phone>82-2-2228-8464</phone>
      <email>jiwonseo1430@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mörtl D, Berger R, Goliasch G, Wojta J, Hülsmann M, Niessner A. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. JACC Heart Fail. 2017 Apr;5(4):268-277. doi: 10.1016/j.jchf.2016.12.008.</citation>
    <PMID>28359415</PMID>
  </reference>
  <reference>
    <citation>Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. doi: 10.1056/NEJMoa1506362. Epub 2015 Nov 5.</citation>
    <PMID>26539835</PMID>
  </reference>
  <reference>
    <citation>Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, Sever S, Camacho A, Wang X, Dande RR, Ibrahim NE, Baron RM, Altintas MM, Wei C, Sheikh-Hamad D, Pan JS, Holliday MW Jr, Januzzi JL, Weisbord SD, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020 Jan 30;382(5):416-426. doi: 10.1056/NEJMoa1911481.</citation>
    <PMID>31995687</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

